VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene®-based discovery of the next generation of angiogenesis targets

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 411-418

  Rudge, J S ^a   Thurston, G ^a   Davis, S ^a   Papadopoulos, N ^a   Gale, N ^a   Wiegand, S J ^a   Yancopoulos, G D ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; DELTA LIKE LIGAND 4; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; AFLIBERCEPT; HYPOXIA INDUCIBLE FACTOR; ISOPROTEIN; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLINDNESS; CANCER; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; EYE DISEASE; GENE; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL; VELOCIGENE; AGE RELATED MACULAR DEGENERATION; ANTIANGIOGENIC THERAPY; ARTICLE; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG MECHANISM; HIGH THROUGHPUT SEQUENCING; IN SITU HYBRIDIZATION; MACULAR DEGENERATION; MALIGNANT NEOPLASM; NEXT GENERATION SEQUENCING; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; TUMOR VASCULARIZATION; VASCULAR REMODELING;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; EYE DISEASES; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746442378     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.052     Document Type: Conference Paper

References (84)

1. Bergsland E.K. 2004. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am. J. Health Syst. Pharm. 1: 61 (21 suppl. 5): S12-20. Review.
2. Brown D.M. et al. IOVS 2006. 47: ARVO E-Abstract 2963.
3. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., Yancopoulos G.D., and Jaffe R.B. 2003. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9: 5721.
4. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6: 389.
5. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435.
6. Cursiefen C., Cao J., Chen L., Liu Y., Maruyama K., Jackson D., Kruse F.E., Wiegand S.J., Dana M.R., and Streilein J.W. 2004. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45: 2666.
7. Dalal S., Berry A.M., Cullinane C.J., Mangham D.C., Grimer R., Lewis I.J., Johnston C., Laurence V., and Burchill S.A. 2005. Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res. 11: 2364.
8. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., and Yancopoulos G.D. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161.
9. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989.
10. Dupont J., Rothenberg M.L., Spriggs D.R., Cedarbaum J.M., Furfine E.S., Cohen D.P., Dancy I., Lee H., Cooper W., and Lockhart A.C. 2005. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 23: 3029.
11. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. 1999. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237: 97.
12. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R., Fandl J.P., Lee F., Carver S., McNay J., Bailey K., Ramakanth S., Hutabarat R., Huang T.T., Radziejewski C., Yancopoulos G.D., and Stahl N. 2003. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nat. Med. 9: 47.
13. Ellis L.M., Takahashi Y., Fenoglio C.J., Cleary K.R., Bucana C.D., and Evans D.B. 1998. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 34: 337.
14. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., and Quaggin S.E. 2003. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111: 707.
15. Eriksson U. and Alitalo K. 1999. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol. 237: 41.
16. Ferrara N. and Henzel W.J. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161: 851.
17. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3: 391.
18. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439.
19. Ferrara N., Chen H., Davis-Smyth T., Gerber H.P., Nguyen T.N., Peers D., Chisholm V., Hillan K.J., and Schwall R.H. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4: 336.
20. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66.
21. Fraser H.M., Dickson S.E., Lunn S.F., Wulff C., Morris K.D., Carroll V.A., and Bicknell R. 2000. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141: 995.
22. Fukasawa M. and Korc M. 2004. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 10: 3327.
23. Gale N.W., Thurston G., Davis S., Wiegand S.J., Holash J., Rudge J.S., and Yancopoulos G.D. 2002. Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harbor Symp. Quant. Biol. 67: 267.
24. Gale N.W., Dominguez M.G., Noguera I., Pan L., Hughes V., Valenzuela D.M., Murphy A.J., Adams N.C., Lin H.C., Holash J., Thurston G., and Yancopoulos G.D. 2004. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. 101: 15949.
25. Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., and Ferrara N. 2000. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60: 6253.
26. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., and Ferrara N. 1999a. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5: 623.
27. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F., Aguet M., and Ferrara N. 1999b. VEGF is required for growth and survival in neonatal mice. Development 126: 1149.
28. Grunweller A. and Hartmann R.K. 2005. RNA interference as a gene-specific approach for molecular medicine. Curr. Med. Chem. 12: 3143.
29. Hazzard T.M., Xu F., and Stouffer R.L. 2002. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol. Reprod. 67: 1305.
30. Heier J.S. et al. IOVS. 2006. 47: ARVO E-Abstract 2959.
31. Hiratsuka S., Minowa O., Kuno J., Noda T., and Shibuya M. 1998. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. 95: 9349.
32. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., and Wiegand S.J. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994.
33. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., and Rudge J.S. 2002. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. 99: 11393.
34. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267: 26031.
35. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., and Jaffe R.B. 2005. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11: 6966.
36. Huang J., Frischer J.S., Serur A., Kadenhe A., Yokoi A., McCrudden K.W., New T., O'Toole K., Zabski S., Rudge J.S., Holash J., Yancopoulos G.D., Yamashiro D.J., and Kandel J.J. 2003. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. 100: 7785.
37. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G., Jr., and Goldberg M.A. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. 93: 10595.
38. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., and Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15: 1751.
39. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., and Ferrara N. 1996. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271: 7788.
40. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841.
41. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R., von Recum H.A., Yuan J., Kamihara J., Flynn E., D'Amato R., Folkman J., and Mulligan R.C. 2001. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. 98: 4605.
42. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306.
43. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., and Fuh G. 2006. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281: 951.
44. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., and Oldfield E.H. 2003. von Hippel-Lindau disease. Lancet 361: 2059.
45. Lu P.Y., Xie F.Y., and Woodle M.C. 2005. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med. 11: 104.
46. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., and Persico M.G. 1991. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. 88: 9267.
47. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., and Yancopoulos G.D. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55.
48. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., and Ullrich A. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835.
49. Miquerol L., Langille B.L., and Nagy A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127: 3941.
50. Mulay M., Limentani S.A., Carroll M., Furfine E.S., Cohen D.P., and Rosen L.S. 2006. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 24: (Abstr.).
51. Nguyen Q.D. et al. IOVS 2006. 47: ARVO E-Abstract 2144.
52. Oliner J., Min H., Leal J., Yu D., Rao S., You E., Tang X., Kim H., Meyer S., Han S.J., Hawkins N., Rosenfeld R., Davy E., Graham K., Jacobsen F., Stevenson S., Ho J., Chen Q., Hartmann T., Michaels M., Kelley M., Li L., Sitney K., Martin F., Sun J.R., Zhang N., Lu J., Estrada J., Kumar R., Coxon A., Kaufman S., Pretorius J., Scully S., Cattley R., Payton M., Coats S., Nguyen L., Desilva B., Ndifor A., Hayward I., Radinsky R., Boone T., and Kendall R. 2004. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507.
53. Olofsson B., Jeltsch M., Eriksson U., and Alitalo K. 1999. Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 10: 528.
54. Orlandini M., Marconcini L., Ferruzzi R., and Oliviero S. 1996. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. 93: 11675.
55. Park J.E., Keller G.A., and Ferrara N. 1993. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4: 1317.
56. Persico M.G., Vincenti V., and DiPalma T. 1999. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr. Top. Microbiol. Immunol. 237: 31.
57. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., and Hicklin D.J. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209.
58. Qaum T., Xu Q., Joussen A.M., Clemens M.W., Qin W., Miyamoto K., Hassessian H., Wiegand S.J., Rudge J., Yancopoulos G.D., and Adamis A.P. 2001. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42: 2408.
59. Ravindranath N., Little-Ihrig L., Phillips H.S., Ferrara N., and Zeleznik A.J. 1992. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131: 254.
60. Rixe O., Verslype C., Meric J.B., Tejpar S., Bloch J., Crabbe M., Khayat D., Furfine E.S., Assadourian S., and Van Cutsem E. 2006. Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 24: (Abstr.).
61. Ryan A.M., Eppler D.B., Hagler K.E., Bruner R.H., Thomford P.J., Hall R.L., Shopp G.M., and O'Neill C.A. 1999. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27: 78.
62. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., and Campochiaro P.A. 2003. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195: 241.
63. Senger D.R., Perruzzi C.A., Feder J., and Dvorak H.F. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629.
64. Shah S.M., Nguyen Q.D., Harriprisad S., Chu K., Holekamp N., Buskey J., Nadler D., Cedarbaum J., and Campochiaro P.A. 2006. A double-masked, placebo-controlled, safety, and tolerability study of intravenous VEGF trap in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 47: (Abstr.).
65. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., and Schuh A.C. 1995. Failure of bloodisland formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62.
66. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., and Sato M. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519.
67. Smith J.K., Mamoon N.M., and Duhe R.J. 2004. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14: 175.
68. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735.
69. Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., and Smith S.K. 1997. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Invest. 77: 607.
70. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., and Yancopoulos G.D. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171.
71. Taipale J., Makinen T., Arighi E., Kukk E., Karkkainen M., and Alitalo K. 1999. Vascular endothelial growth factor receptor-3. Curr. Top. Microbiol. Immunol. 237: 85.
72. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., and Bohlen P. 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187: 1579.
73. Tomisawa M., Tokunaga T., Oshika Y., Tsuchida T., Fukushima Y., Sato H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N., and Nakamura M. 1999. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer 35: 133.
74. Valenzuela D.M., Griffiths J.A., Rojas J., Aldrich T.H., Jones P.F., Zhou H., McClain J., Copeland N.G., Gilbert D.J., Jenkins N.A., Huang T., Papadopoulos N., Maisonpierre P.C., Davis S., and Yancopoulos G.D. 1999. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. 96: 1904.
75. Valenzuela D.M., Murphy A.J., Frendewey D., Gale N.W., Economides A.N., Auerbach W., Poueymirou W.T., Adams N.C., Rojas J., Yasenchak J., Chernomorsky R., Boucher M., Elsasser A.L., Esau L., Zheng J., Griffiths J.A., Wang X., Su H., Xue Y., Dominguez M.G., Noguera I., Torres R., Macdonald L.E., Stewart A.F., DeChiara T.M., and Yancopoulos G.D. 2003. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat. Biotechnol. 21: 652.
76. Volm M., Koomagi R., and Mattern J. 1997. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 74: 64.
77. Wachsberger P., Burd R., Marrero N., Rossetti D., Strickler T., Yancopoulos G., Holash J., and Dicker A. 2005. Improvement of fractionated radiation therapy by combination with a VEGF blocker, VEGF Trap. Annual Meeting of the Radiation Research Society, Denver, Colorado. (Abstr. PP189).
78. Wiegand S., Cao J., Renard R., Rudge J., and Yancopoulos G. 2003. Long-lasting inhibition of corneal neovascularization following systemic administration of the VEGF Trap. Invest. Ophthalmol. Vis. Sci. 44: (E-Abstr. 829).
79. Wiegand S.J., Zimmer E., Nork T.M., Miller P.E., Christian B.J., Miller J.M., Cao J., Cedarbaum J., Yancopoulos G.D., and Furfine E. 2005. VEGF Trap both prevents experimental choroidal neovascularization and causes regression of established lesions in non-human primates. Invest. Ophthalmol. Vis. Sci. 46: (E-Abstr. 1411).
80. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407: 242.
81. Yang J.C. 2004. Bevacizumab for patients with metastatic renal cancer: An update. Clin. Cancer Res. 10: 6367S.
82. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., and Rosenberg S.A. 2003. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427.
83. Yoshiji H., Gomez D.E., Shibuya M., and Thorgeirsson U.P. 1996. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56: 2013.
84. Zimmermann R.C., Xiao E., Husami N., Sauer M.V., Lobo R., Kitajewski J., and Ferin M. 2001. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J. Clin. Endocrinol. Metab. 86: 768.